马斯克的 Neuralink 计划 2026 年量产脑机接口，同步推出全自动化手术方案 —— 电极丝可直接穿过硬脑膜无需切除，规避传统侵入式设备的创伤问题， 兼顾效率与成本控制。 OpenAI CEO Altman 的 Merge Labs 拆分独立，专攻超声波脑机接口，与马斯克形成对垒，印证技术商业化潜力； 国内格式塔也布局该路线，2026 年脑机 接口将迈入商业化，场景拓展至 AI、机器人领域。 Neuralink 的量产 + 自动化手术，加上 Merge 的超声波脑机布局，有两层意义： 1、脑机接口要从 "医疗试验工具" 变成能普及的产品 —— 相当于从实验室原型机，进到能批量卖的阶段； 2、等技术更成熟，Neuralink 的脑机接口就能和特斯拉 Optimus 人形机器人联动，为后续协同应用打基础。 01 什么是脑机接口 脑机接口（BCI）是大脑与外部设备的直连通信系统，无需手、嘴等常规通路即可互换信息，分三个模块： "脑" 是思维信号的产生源，"机" 是接收信号 执行动作的设备（如电脑、假肢），"接口" 是核心翻译器，负责读写脑信号与转换设备指令，实现想法与设备动作的对应。 脑机接口的关键在 "接 ...

真没想到，脑机接口概念股又爆了！ 今年第一个交易日，脑机接口板块再次爆发，板块内51家成分股中有29家涨停，涨幅超过10%达到了惊人的40家。 1月5日，河南上市公司翔宇医疗（证券代码：688626.SH）收获今年首个20CM涨停，报收于72.6元/股，创下四年半来的新高。事实上，在经历近4个月的 回调后，自去年12月12日以来，翔宇医疗已经重拾涨势，15个交易日累计涨幅达到53%。 在此期间，公司获得接连不断的机构调研，12月22日—29日，公司陆续发布2则公告，近10天时间里接待了71家机构。 股价15天涨了53% 自去年以来，翔宇医疗的股价表现可谓抢眼。截至今年1月5日，翔宇医疗股价已经累计上涨了149.06%。 1月5日，翔宇医疗时隔半年再次收获"20CM"涨停，股价创下四年半来的新高。 翔宇医疗于2021年3月31日登陆A股上市，上市初始出现一波大涨，在当年6月28日盘中创出120.13元的历史最高点。 回顾翔宇医疗上市以来的走势可以看到，他们在2021年6月下旬创出120.13元历史最高点，之后就开始走出了长达3年的下跌行情，一直到2024年9月，翔 宇医疗整体趋势就是震荡走低，但是中间波动还是比 ...

Group 1 - The core index of the robot industry, the National Certificate Robot Industry Index, rose by 0.9%, with notable increases in stocks such as Hanwei Technology up over 15% and Tianzhihang-U up over 9% [1] - The robot ETF E Fund (159530) saw a trading volume exceeding 1 billion yuan, with net subscriptions surpassing 130 million shares, marking a new high of 15.2 billion yuan since its inception [1] - The humanoid robot industry has made significant progress over the past year, transitioning from product development to initial commercialization, with projections indicating that 14,000 humanoid robots could be shipped in China by 2026, doubling annually and potentially reaching over 1 million units by 2034 [1] Group 2 - The National Certificate Robot Industry Index focuses on humanoid robots and core components, covering companies like Sanhua Intelligent Control and Lingyi Technology, which together account for approximately 80% of the index, leading other similar indices [2] - Investors can leverage products like the robot ETF E Fund (159530) to gain exposure to opportunities within the humanoid robot industry chain [2]

Core Viewpoint - The brain-computer interface (BCI) concept stocks surged on the first trading day of 2026 in the A-share market, driven by significant developments in the industry, including Neuralink's plans for mass production of BCI devices and supportive policies for high-end medical devices [1][3]. Group 1: Stock Performance - Multiple BCI-related stocks, including Aipeng Medical, Xiangyu Medical, and Meihua Medical, reached their daily limit up, with Aipeng Medical rising by 20% to 33.30 CNY [2][1]. - Other notable performers included Sainuo Medical and Hanwei Technology, which saw increases of 17.31% and 15.99%, respectively [2][1]. - The overall trend in the Hong Kong market mirrored that of the A-share market, with stocks like Nanjing Panda Electronics rising over 30% [2][1]. Group 2: Industry Developments - Elon Musk's Neuralink announced plans to begin large-scale production of BCI devices in 2026, signaling a significant advancement in the field [3]. - The integration of artificial intelligence in healthcare is accelerating, with 207 AI medical devices expected to be approved by 2025, highlighting the rapid technological progress [3]. - The global BCI market is projected to reach $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17% from 2025 to 2034, indicating substantial growth potential [3]. - Recent policy support, including the inclusion of implantable BCI devices in a priority approval list by the National Medical Products Administration, is expected to further enhance the commercialization process [3].

Market Overview - The A-share market saw a strong opening on January 5, with the Shanghai Composite Index returning to 4000 points, closing at 4011.45, up 1.07% [1] - The Shenzhen Component Index rose by 1.87%, and the ChiNext Index increased by 2.15% [1] Trading Volume - The total trading volume in the Shanghai and Shenzhen markets reached 1.64 trillion yuan, an increase of 323.8 billion yuan compared to the previous trading day [3] Stock Performance - A total of 4064 stocks rose, with 99 stocks hitting the daily limit, while 1236 stocks declined [3] - The sectors that performed well included insurance, medical devices, semiconductors, and gaming, with brain-computer interface concept stocks experiencing significant gains [3] Sector Highlights Brain-Computer Interface - Brain-computer interface stocks surged, with several companies hitting the daily limit [6] - Notable performers included Xiangyu Medical, Guanhao Biological, Meihua Medical, Aipeng Medical, and Lepu Medical, all recording a 20% increase [6][7] - Elon Musk's Neuralink announced plans for large-scale production of brain-computer interface devices by December 31, 2026, which is expected to revolutionize the field by reducing invasiveness [9] Semiconductor Sector - The semiconductor sector also showed strength, with multiple stocks reaching their daily limit [10] - Key performers included Dongwei Semiconductor and *ST Tianlong, both achieving a 20% increase [11] - TSMC announced it received U.S. government approval to import chip manufacturing equipment to its Nanjing facility in 2026, which is a positive development for the sector [12] Insurance Sector - The insurance sector experienced a rally, with significant gains from major companies [13] - Xinhua Insurance rose by 7.53%, China Pacific Insurance by 6.16%, and China Life Insurance by over 5% [13][14] - The insurance industry reported a total premium income of 57.629 billion yuan for the first 11 months of 2025, a year-on-year increase of 7.6% [14]

【导读】上午A股三大指数集体大涨，半导体、保险板块大涨，脑机接口概念股掀"涨停潮" 大家好，今天是2026年第一个交易日，基金君和你继续关注市场行情！ 1月5日上午，A股三大股指高开高走，沪指重返4000点，超4000只个股上涨，近百只个股涨停。截至午间收盘，沪指报4011.45点，涨1.07%，深证成指涨 1.87%，创业板指涨2.15%。 沪深两市半日成交额达1.64万亿元，较上个交易日放量3238亿元。个股涨多跌少，全市场共4064只个股上涨，99只个股涨停，有1236只个股下跌。 个股方面，翔宇医疗、冠昊生物（300238）、美好医疗（301363）、爱朋医疗（300753）、乐普医疗（300003）录得20cm涨停，三七互娱（002555）、 创新医疗（002173）、航天长峰（600855）录得10cm涨停。 | 代码 | 名称 | 现价 | 涨跌幅 ▼ | 总市值1 | 年初至今涨跌幅 | | --- | --- | --- | --- | --- | --- | | 688626 | 翔宇医疗 | 72.60 | 20.00% | 116亿 | 20.00% | | 300238 | 冠昊生物 ...

每经AI快讯，1月5日，脑机接口概念盘中持续扩大涨幅，博拓生物、航天长峰（600855）封涨停，此 前倍益康、三博脑科（301293）、翔宇医疗、伟思医疗、诚益通（300430）等近20股涨停，冠昊生物 （300238）、狄耐克（300884）、中科信息（300678）、汉威科技（300007）、道氏技术（300409）等 多股涨超10%。 ...

2026.01. 05 | 09:34 % | | | | 11 2 75 | | 09:34 % | | | | | .11 ? 75 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | < W | | | 宇树机器人指数(8841902) | | | Q < w | | | 机器人指数(884126) | | Q | | | | | 01-05 09:34:38 | | | | | | 01-05 09:34:27 | | | | 2681.33 | | 昨收 | 2703.07 | 成交额 | 32.8亿 | 9393.47 | | 昨夜 | 9410.62 | 成交额 | 83.5亿 | | -21.74 | -0.80% | 今开 | 2675.92 | 成交量 | 8857.7万 | -17.16 | -0.18% | 六分 | 9413.89 | 成交量 | 3.41Z | | 上 涨 | 5 | 即 程 | 1 | 下 跌 | 22 | 上涨 | 37 | 中 品 | 5 | 下 跌 | 7 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ A股2026年迎"开门红"，第一个交易日开盘后一路上涨！ 1月5日，沪指拉升涨0.9%，时隔34个交易日，上证指数盘中重回4000点。 上证指数 ◀ ） @ 1A0001 LT 2.69亿 4004.59 高 4004.59 开 3986.97 量 0.57% 额 4862.0亿 35.75 0.90% 低 3983.58 换 A 相关 ETF 2 上证指数ETF汇添富 0.80% 含上证指数 100% ● > 分时 日K 周K 月K 五日 更多▼ (0) 领先4016 最新:4004.59 +35.75 +0.90% 4016.47 +1.20% - - 0.00% 3921.21 -1.20% 09:30 15:00 11:30 1749.39万 分时量 ▼ 2 量:2034430 现手:92480 L 【好消息】您可升级为 T+0交易! × 早盘半导体产业链震荡拉升，设备、材料、晶圆代工方向均表现不俗，中微公司、矽电股份、东微半导 涨超10%，华虹公司、中芯国际、拓荆科技、华海清科、中科飞测、盛美上海跟涨。消息面上，华虹公 司发布 ...

Core Viewpoint - Neuralink plans to start large-scale production of brain-machine interface devices in 2026, with a focus on highly automated surgical procedures that eliminate the need to remove the dura mater for electrode insertion [2][4]. Group 1: Neuralink's Developments - Neuralink aims to simplify the surgical process and enhance efficiency and cost-effectiveness through automation, marking a significant advancement in invasive brain-machine interface technology [2][4]. - The company has completed a $650 million Series E funding round in 2025, achieving a valuation of approximately $9 billion [4]. - As of September 2025, 12 individuals have undergone Neuralink device implantation, with a total usage time exceeding 15,000 hours [4]. Group 2: Market and Industry Trends - The brain-machine interface market is projected to grow to approximately $12.4 billion by 2034, with a CAGR of 17% from 2025 to 2034 [5]. - The anticipated commercialization of brain-machine interfaces is expected to transition from medical necessity to applications in AI and robotics [2][5]. - Related companies in the A-share market are expected to benefit from Neuralink's scaling production and technological breakthroughs [5]. Group 3: Future Prospects - Neuralink's future product upgrades include increasing electrode channels to 3,000 by 2026 and 10,000 by 2027, with a long-term goal of over 25,000 channels by 2028 [4]. - The collaboration between Neuralink and the Optimus robot is expected to redefine human-robot interaction and explore the potential of integrating human brain functions with AI [3][4].